Krystal Biotech Salute del bilancio
Salute finanziaria criteri di controllo 6/6
Krystal Biotech has a total shareholder equity of $838.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $917.7M and $78.8M respectively. Krystal Biotech's EBIT is $4.0M making its interest coverage ratio -0.1. It has cash and short-term investments of $559.6M.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
US$0
Debito
| Indice di copertura degli interessi | -0.1x |
| Contanti | US$559.61m |
| Patrimonio netto | US$838.89m |
| Totale passività | US$78.77m |
| Totale attività | US$917.66m |
Aggiornamenti recenti sulla salute finanziaria
We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02
Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Recent updates
Krystal Biotech: Q4 Catalysts Expected With VYJUVEK Revenue Growth Pressing On
Oct 14Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
Jul 31Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think
May 13Krystal Biotech's Future Brightens With Vyjuvek's Robust Launch
Feb 28Krystal Biotech: Ready For Launch
Feb 20We Think Krystal Biotech (NASDAQ:KRYS) Can Easily Afford To Drive Business Growth
Jan 02Companies Like Krystal Biotech (NASDAQ:KRYS) Can Afford To Invest In Growth
Sep 06Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 46%?
Aug 08We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
May 17We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Jan 30Krystal Biotech cleared to file EU marketing application for rare skin disease therapy
Sep 22We Think Krystal Biotech (NASDAQ:KRYS) Can Afford To Drive Business Growth
Aug 30Krystal Biotech: Solid Performance, Let's Keep Holding
Aug 18Krystal Biotech GAAP EPS of -$1.10 misses by $0.07
Aug 08Krystal gets FDA nod to start trial of gene therapy KB407 for cystic fibrosis
Aug 01Krystal Biotech: High Potential, Buy-At-Dips Stock
May 25We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely
Apr 20Krystal Biotech: The Future Looks More And More Derisked
Feb 21Krystal Biotech Establishes Proof Of Concept With STAR-D Platform; Opens Door For More Skin Indications
Nov 30Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout
Sep 27Here's Why We're Not Too Worried About Krystal Biotech's (NASDAQ:KRYS) Cash Burn Situation
Sep 25Companies Like Krystal Biotech (NASDAQ:KRYS) Are In A Position To Invest In Growth
Jun 17Analisi della posizione finanziaria
Passività a breve termine: KRYS's short term assets ($682.8M) exceed its short term liabilities ($71.9M).
Passività a lungo termine: KRYS's short term assets ($682.8M) exceed its long term liabilities ($6.9M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: KRYS is debt free.
Riduzione del debito: KRYS had no debt 5 years ago.
Copertura del debito: KRYS has no debt, therefore it does not need to be covered by operating cash flow.
Copertura degli interessi: KRYS has no debt, therefore coverage of interest payments is not a concern.